Lev Pharmaceuticals Inc. (LEVP.OB) Granted Authorization to File for European Distribution Rights for Lead Drug Candidate
Source: http://Blog.QualityStocks.net/?p=10898Posted on Tuesday, July 1st, 2008 | In Current Market News, OTCBB Markets, Small & Micro Cap, Stocks to Watch
Lev Pharmaceuticals Inc. (OTCBB: LEVP) develops and commercializes therapeutic products for inflammatory diseases. Its lead product candidate, Cinryze (C1 inhibitor), is for the treatment of angioedema (HAE).
The company today announced today a letter of agreement with the Sanquin Blood Supply Foundation, which gives Lev the OK to file for European marketing authorization of C1 to treat the life-threatening attacks associated with HAE, such as inflammation of the larynx, abdomen, face, extremities and urogenital tract. Lev also received authorization from the European Medicines Agency (EMEA) to submit an application for C1 for Community Marketing Authorization through the centralized European registration procedure.
An estimated 10,000 people in the United States suffer from HAE. Per the agreement with Sanquin, Lev holds exclusive rights to market and distribute C1 for the treatment of HAE in North America, and is in discussions with Sanquin to expand distribution to certain European countries.
Lev intends to submit its application to the EMEA in the fourth quarter of 2008, though there is no guarantee Lev will win European rights, or that EMEA will approve any application for Community Marketing Authorization filed by Lev.
Let us hear your thoughts below:
Last 5 posts by QualityStocks
- Omnicity Corp. (OMCY.OB) Announces Addition of New Board Member - November 20th, 2009
- Muscle Flex, Inc. (MFLI.PK) Announces Release Time for the BUDDY Tablet Caddy Two-Minute Commercial and Landing Page - November 20th, 2009
- Artfest International, Inc. (ARTS.OB) Announces Revenue Profit Jumps - November 20th, 2009
- Omnicity Corp.’s (OMCY.OB) Recently-Issued Corporate Update - November 20th, 2009
- Soligenix Inc. (SNGX.OB) Taking Steps to Meet Challenges of Vaccine Technology and Biological Warfare - November 20th, 2009
Abdomen, Angioedema, Blood Supply, Community Marketing, Current Market News, Distribution Rights, Drug Candidate, European Countries, European Medicines, Extremities, Inflammatory Diseases, Lev Pharmaceuticals, Levp, Medicines Agency, Otcbb, OTCBB Markets, Pharmaceuticals Inc, Product Candidate, Registration Procedure, Sanquin Blood Supply Foundation, Small & Micro Cap, Stocks to Watch, Therapeutic Products, Urogenital Tract
 About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.